Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 806-826

  Mehta, Parinda A ^a   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Alternative donor HCT for children with ALL; Biologic differences between pediatric and adult ALL; Cellular genotype defines major forms of childhood acute lymphoblastic leukemia; Hematopoietic cell transplantation for acute lymphoblastic leukemia in children; Outcomes of transplantation in second or subsequent remission; Role of second transplant procedures for posttransplant relapse; Sibling donor transplantation in children with ALL; Transplantation in children with Down's syndrome and ALL; UCB transplantation for children with ALL

Indexed keywords

EID: 84856271260     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch56     Document Type: Chapter

References (234)

1. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-30.
2. van Dongen JJM, Adriaansen HJ. Immunobiology of leukemia. In: Henderson ES, Lister TA, Greaves MF, editors. Leukemia, 6th edn. Philadelphia: WB Saunders; 1996. pp. 83-130.
3. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B- lineage and monocytic characteristics. Blood 1985; 65: 21-31.
4. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-9.
5. Kersey JH. Commentary on 50 years of studies of the biology and therapy of childhood leukemia. Blood 1998; 92: 1838.
6. Rubnitz JE, Downing JR, Pui CH et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150-7.
7. Suryanarayan K, Hunger SP, Kohler S et al. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 1991; 77: 324-30.
8. Chen CS, Sorensen HB, Domer H et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variable and poor outcome. Blood 1993; 81: 2386-93.
9. Pui CH, Behm FG, Downing JR et al. 11q23/ MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-15.
10. Cimino G, Rapanotti MC, Rivolta A et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995; 9: 391-5.
11. Pui CH, Ribeiro RC, Campana D et al. Prognostic factors in the acute lymphoid and myeloid leukemias of childhood. Leukemia 1996; 10: 952-6.
12. Taki T, Ida K, Bessho F et al. Frequency and the clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996; 10: 1303-7.
13. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-68.
14. Perentesis JP. Why is age such an important prognostic factor in acute lymphoblastic leukemia?. Leukemia 1997 (Suppl.4): S4-7.
15. Greaves MF, Pegram SM, Chan LC. Collaborative group study of epidemiology of acute lymphoblastic leukemia subtypes: background and first report. Leuk Res 1985; 9: 715-33.
16. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia. Leukemia 1993; 7: 349-60.
17. Parkin, DNM, Stiller CA, Draper GJ, Bieber CA. The international incidence of cancer. Int J Cancer 1988; 42: 511-20.
18. Linet MS, Devesa SS. Descriptive epidemiology of childhood leukemia. Br J Cancer 1991; 63: 424-9.
19. Williams CKO, Folami AO, Laditan AAO, Ukaejiofo EO. Childhood acute leukemia in a tropical population. Br J Cancer 1982; 46: 89-94.
20. Fleming AF. Epidemiology of the leukemias in Africa - an overview. Leuk Res 1985; 9: 735-40.
21. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.
22. Graf T. Leukemia as a multi-step process: studies with avian retroviruses containing two oncogenes. Leukemia 1988; 2: 127-31.
23. Alexander FA, Ricketts JT, McKinney PA, Cartwright RA. Community lifestyle characteristics and risk of acute lymphoblastic leukemia in children. Lancet 1990; 336: 1461-5.
24. Kinlen LJ, Clarke K, Hudson C. Evidence from population mixing in British new towns 1946- 1985 of an infective basis for childhood leukemia. Lancet 1990; 339: 557-82.
25. Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol 2003; 7: 233-45.
26. Greaves M. In utero origins of childhood leukaemia. Early Hum Dev 2005; 81: 123-9.
27. Crist WM, Grossi CE, Pullen DJ, Cooper MD. Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 1985; 12: 105-21.
28. Crist W, Pullen J, Boyett J et al. Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis-a Pediatric Oncology Group study. J Clin Oncol 1988, 6: 34-43.
29. Pui CH, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-62.
30. Hoelzer D, Thiel T, Loffler H et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984; 64: 38-47.
31. Clarkson B, Ellis S, Little C et al. Acute lymphoblastic leukemia in adults. Semin Oncol 1985; 12: 160-79.
32. Bowman WP, Melvin SL, Aur RJ, Mauer AM. A clinical perspective on cell markers in acute lymphocytic leukemia. Cancer Res 1981; 41: 4794-801.
33. Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48: 179-97.
34. Gingrich RD, Burns GCP, Armitage JO et al. Long term relapse-free survival in adult acute lymphoblastic leukemia. Cancer Treatment Reps 1985; 69: 153-60.
35. Czuczman MS, Dodge RK, Stewart CC et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931-9.
36. Uckun FM, Steinherz PG, Sather H et al. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia - a Children's Cancer Group Study. Blood 1996; 88: 4288-95.
37. Kaspers GJ, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751-6.
38. Trueworthy R, Shuster J, Look T et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol 1992; 10: 606-13.
39. Whitehead VM, Vucich MJ, Lauer SJ et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) Blineage acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1992; 80: 1316-23.
40. Golub TR, Barker GF, Bohlander SK et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995; 92: 4917-21.
41. Romana SP, Mauchaffe M, Le Coniat M et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML-1 gene fusion. Blood 1991; 85: 3662-70.
42. Shurtleff SA, Buijs A, Behm FG et al. TELAML1 fusion resulting from a cryptic t(12:21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-9.
43. Raynaud S, Cave H, Baens M et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-9.
44. McClean TW, Ringold S, Neuberg D et al. TELAML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-8.
45. Shih LY, Chou TB, Liang DC et al. Lack of TELAML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996; 10: 1456-8.
46. Raynaud S, Mauvieux L, Cayuela JM et al. TEL/ AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 1996; 10: 1529-30.
47. Aguiar RC, Sohal J, van Rhee F et al. TEL-AML1 fusion in acute lymphoblastic leukemia of adults. MRC Adult Leukemia Working Party. Br J Haematol 1996; 95: 673-7.
48. Kantarjian HM. Adult acute lymphocytic leukemia: critical review of current knowledge. Am J Med 1994; 97: 176-84.
49. Aricò M, Grazia Valsecchi M, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
50. Rivera GK, Hudson MM, Liu Q et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996; 88: 831-7.
51. Bordigoni P, Vernant JP, Souillet G et al. Allogeneic marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de al Greffe de Moelle Osseuse. J Clin Oncol 1989; 7: 747-53.
52. von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Société Française de Greffe de Moelle. Bone Marrow Transpl 1995; 16: 521-7.
53. Saarinen UM, Mellander L, Nysom K et al. Allogeneic bone marrow transplantation in first remission for children with very high risk acute lymphoblastic leukemia: a retrospective casecontrol study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO) Bone Marrow Transplant 1996; 17: 357-63.
54. Chessells JM, Bailey C, Wheeler K et al. Bone marrow transplantation for high-risk childhood lymphoblastic leukemia in first remission: experience in MRC UKALL X. Lancet 1992; 8819: 656-8.
55. Satwani P, Sather H, Ozkaynak F et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a Children's Oncology Group Study Report. Biol Blood Marrow Transplant 2006; 13: 218-27.
56. Balduzzi A, Valsecchi M, Uderzo C et al. Chemotherapy versus allogeneic transplantation for very high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-42.
57. Ribera JM, Ortega J J, Oriol A et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as post-remission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trail. J Clin Oncol 2007; 25: 16-24.
58. Schultz KR, Pullen DJ, Sather HN et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926-35.
59. Sanders JE, Thomas ED, Buckner CD, Doney K. Marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 1987; 70: 324-6.
60. Brochstein JA, Kernan NA, Groshen S et al. Allogeneic bone marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317: 1618-24.
61. Woods WG, Nesbit ME, Ramsay NK et al. Intensive therapy followed by bone marrow transplantation for patients with acute lymphocytic leukemia in second or subsequent remission: determination of prognostic factors (a report from the University of Minnesota Bone Marrow Transplantation Team). Blood 1983; 61: 1182-9.
62. Weisdorf DJ, Woods WG, Nesbit ME et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 1994; 86: 62-9.
63. Parsons SK, Castellino SM, Lehmann LE et al. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant 1996; 17: 763-8.
64. Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996; 18: 489-94.
65. Boulad F, Steinherz P, Reyes B et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197-207.
66. Bleakley M, Shaw PJ, Nielsen JM. Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor. Bone Marrow Transplant 2002; 30: 1-7.
67. Dopfer R, Henze G, Bender-Gotze C et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 1991; 78: 2780-4.
68. Weyman C, Graham-Pole J, Emerson S et al. Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey. Bone Marrow Transplant 1993; 11: 43-50.
69. Barrett AJ, Horowitz MM, Pollock BH et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331: 1253-8.
70. Moussalem M, Esperou Bourdeau H, Devergie A et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transpl 1995; 15: 943-7.
71. Uderzo C, Rondelli R, Dini G et al. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. Br J Haematol 1995; 89: 790-7.
72. Torres A, Alvarez MA, Sanchez J et al. Allogeneic bone marrow transplantation vs chemotherapy for the treatment of acute lymphoblastic leukaemia in second complete remission (revisited 10 years on). Bone Marrow Transplant 1999; 23: 1257-60.
73. Davies SM, Ramsay NKC, Klein JP et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340-7.
74. Vicent MG, Madero L, Martinez A et al. Matchedpair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia. Bone Marrow Transplant 2002; 30: 9-13.
75. Eapen M, Raetz E, Zhang M et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children 823 Marrow Transplant Research. Blood 2006; 107: 4961-7.
76. Borgmann A, von Stackelberg A, Hartmann R et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-9.
77. Feig SA, Harris RE, Sather HN. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children's Cancer Group (CCG-1884). Med Pediatr Oncol 1997; 29: 534-40.
78. Coccia PF, Strandjord SE, Warkentin PI et al. High-dose cytosine arabinoside and fractionated total body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888-93.
79. Woods WG, Ramsay NKC, Weisdorf DJ et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990; 6: 9-16.
80. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14: 2276-85.
81. Gaynon PS, Qu RP, Chappell RJ et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group experience. Cancer 1998; 82: 1387-95.
82. Buhrer C, Hartmann R, Fengler R et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group. J Clin Oncol 1996; 14: 2812-17.
83. Camitta BM, Pullen J, Murphy S. Biology and treatment of acute lymphocytic leukemia in children. Semin Oncol 1997; 24: 83-91.
84. Uderzo C, Valsecchi MG, Bacigalupo A et al. Treatment of childhood acute lymphoblastic leukemia in second remission with bone marrow transplantation and chemotherapy: ten year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 134: 352-8.
85. Gustafsson G, Schmiegelow K, Forestier E et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000; 14: 2267-75.
86. Vilmer E, Suciu S, Ferster A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257-66.
87. Silverman LB, Declerck L, Gelber RD et al. Results of Dana-Farber Cancer Institute protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14: 2247-56.
88. Kamps WA, Veerman AJJP, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000; 14: 2240-6.
89. Harms DO, Janka-Schaub GE on behalf of the COALL Study Group. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-9.
90. Gaynon PS, Trigg ME, Heerema NA et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-33.
91. Schrappe M, Reiter A, Zimmermann M et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-22.
92. Conter V, Aricò M, Valsecchi MG et al. Longterm results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982-1995. Leukemia 2000; 14: 2196-204.
93. Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
94. Marks DI, Bird JM, Cornish JM et al. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 931-6.
95. Sierra J, Radich J, Hansen JA et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997; 90: 1410-14.
96. Roy A, Bradburn M, Moorman AV et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129: 35-44.
97. Talano JM, Casper JT, Camitta BM et al. Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant 2006; 37: 135-41.
98. Heerema NA, Harbott J, Galimberti S et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 2004; 18: 693-702.
99. Primo D, Tabernero MD, Rasillo A et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003; 17: 1124-9.
100. Robinson HM, Matineau M, Harris RL et al. Derivative chromosome 9 deletions are a signifi- cant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia. Leukemia 2005; 19: 564-71.
101. Secker-Walker LM, Lawler SD, Hardisty RM. Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br Med J 1978; 2: 1529-30.
102. Yanada M, Takeuchi J, Sugiura I et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia study group. J Clin Oncol 2006; 24: 460-6.
103. Wassmann B, Pfeifer H, Goekbuget N et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-fine therapy for Philadelphia- positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469-77.
104. Towatari M, Yanada M, Usui N et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507-12.
105. De Labarthe A, Roousselot P, Huguet-Rigal F et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-13.
106. Lee KH, Lee, JH, Choi SJ et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome- positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509-16.
107. Lee S, Kim YJ, Min CK et al. The effect of firstline imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 2005; 105: 3449-57.
108. Kolb EA, Pan Q, Ladanyi M et al. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003; 98: 2643-50.
109. Carpenter PA, Snyder DS, Flowers ME et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-3.
110. Heerema NA, Nachman JB, Sather HN et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1999; 94: 4036-46.
111. Raimondi SC, Zhou Y, Mathew S et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003; 98: 2715-22.
112. Nachman JB, Heerema NA, Sather H et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 1112-15.
113. Nachman JB, Sather HN, Sensel MG et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 388: 1663-71.
114. Aricò M, Grazia Valsecchi M, Conter V et al. for the Associazione Italiana di Ematologia ed Oncologia Pediatrica. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002; 100: 420-6.
115. Nyvold C, Madsen HO, Ryder LP et al., on behalf of the Nordic Society for Pediatric Hematology and Oncology. Precise quantification of minimal residual disease at day 29 allows identification of 824 Chapter 56 children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-8.
116. Dworzak MN, Fröschi G, Printz D et al., for the Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-8.
117. Tarusawa M, Yashima A, Endo M, Maesawa C. Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction. Int J Hematol 2002; 75: 166-73.
118. Willemse MJ, Seriu T, Hettinger K et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386-93.
119. Coustan-Smith E, Sancho J, Behm FG et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-8.
120. Wheeler KA, Richards SM, Bailey CC et al., for the Medical Research Council Working Party on Childhood Leukaemia. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI. Blood 2000; 96: 2412-18.
121. Horowitz MM, Przepiorka D, Champlin RE et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?. Blood 1992; 79: 2771-4.
122. Frassoni F, Labopin M, Powles R et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000; 355: 1393-8.
123. Wheeler K, Richards S, Bailey C, Chessells J, for the Medical Research Council Working Party on Childhood Leukaemia. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Br J Haematol 1998; 101: 94-103.
124. Schroeder H, Garwicz S, Kristinsson J et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995; 25: 372-8.
125. Borgmann A, Hartmann R, Schmid H et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Bone Marrow Transplant 1995; 15: 515-21.
126. Eapen M, Raetz E, Zhang M et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006; 107: 4961-7.
127. Hijiya N, Hudson MM, Lensing S et al. Cumulative incidence of secondary neoplasm as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297: 1207-15.
128. Zuna J, Cave H, Eckert C et al. Childhood secondary ALL after ALL treatment. Leukemia 2007; 21: 1431-5.
129. Duell T, van Lint MT, Ljungman P et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184-92.
130. Cerveri I, Zoia MC, Fulgoni P et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54: 131-5.
131. Uderzo C, Pilion M, Corti P et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Disease and Late Effects Working Parties. Bone Marrow Transplant 2007; 39: 667-75.
132. Kernan NA, Boulad F, Small TN et al. Improved outcome with T-cell depleted (SBA-E-) marrow transplants from related and unrelated donors for children with acute leukemia transplanted in first or second remission [Abstract]. Blood 2001; 98: 2821.
133. Blume KG, Forman SJ, O'Donnell MR et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015-20.
134. Schmitz N, Gassmann W, Rister M et al. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 1988; 72: 1567-73.
135. Snyder DS, Chao NJ, Amylon MD et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82: 2920-8.
136. Jamieson CH, Amylon MD, Wong RM et al. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first, or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol 2003; 31: 981-6.
137. Gassas A, Sung L, Saunders EF et al. Comparative outcome of hematopoietic stem cell transplantation pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant 2006; 38: 739-43.
138. Marks DI, Forman SJ, Blume KG et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006; 12: 438-53.
139. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-8.
140. Bunin N, Aplenc R, Kamani N et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32: 543-8.
141. Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-72.
142. Filipovich AH, Ramsay NK, Arthur DC, McGlave PB, Kim T, Kersey JH. Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone and methotrexate for prophylaxis of graft-versus-host disease. Transplantation 1985; 39: 282-5.
143. Bozdech MJ, Sondel PM, Trigg ME et al. Transplantation for haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985; 13: 1201-10.
144. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-71.
145. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
146. Ash RC, Horowitz MM, Gale RP et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991; 7: 443-52.
147. Szydlo R, Goldman JM, Klein JP et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-77.
148. Munn RK, Henslee-Downey PJ, Romond EH et al. Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant 1997; 19: 421-7.
149. Ruggeri L, Campanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
150. Klingebiel T, Handgretinger R, Lang P et al. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004; 18: 181-92.
151. Marks DI, Khattry N, Cummins M et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006; 134: 196-201.
152. Beatty PG, Kollman C, Howe CW. Unrelateddonor marrow transplants: the experience of the National Marrow Donor Program. Clin Transplant 1995; 271-7.
153. Stroncek DF, Holland PV, Bartsch G et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993; 81: 1940-6.
154. Schreuder GM, Hurley CK, Marsh SG et al. The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5 and DQB1 alleles and their association with serologically defined HLA-A,-B,-C,- DR and DQ antigens. Eur J Immunogenet 2001; 28: 565-96.
155. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children 825 the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-83.
156. Davies SM, Ramsay NKC, Weisdorf DJ. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 1996; 17: 737-40.
157. Barker JN, Krepski TP, Davies SM et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8: 257-60.
158. Hurley CK, Wagner JEL, Setterholm MI et al. Advances in HLA: practical implication for selecting adult donors and cord blood units. Biol Blood Marrow Transplant 2006; 12: 28-33.
159. Davies SM, Shu XO, Blazar BR et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995; 86: 1636-42.
160. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-8.
161. Green A, Clarke E, Hunt L et al. Children with acute lymphoblastic leukemia who receive T-celldepleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood 1999; 94: 2236-46.
162. Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997; 15: 557-65.
163. Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-71.
164. Saarinen-Pihkala UM, Gustafsson G, Ringdén O et al., for the Nordic Society of Pediatric Hematology and Oncology. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19: 3406-14.
165. Dahlke J, Kroger N, Zabelina T et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006; 37: 155-63.
166. Eapen M, Rubinstein P, Zhang M-J et al. Comparable long-term survival after unrelated and HLAmatched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145-51.
167. Lawson SE, Harrison G, Richards S et al., on behalf of the MRC Childhood Leukaemia Working Party. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol 2000; 108: 531-43.
168. Borgmann A, von Stackelberg A, Hartmann R et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-9.
169. Bunin N, Carston M, Wall D et al., and the National Marrow Donor Program Working Group. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002; 99: 3151-7.
170. Woolfrey AE, Anasetti C, Storer B et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002; 99: 2002-8.
171. Al-Kasim FA, Thornley I, Rolland M et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002; 116: 483-90.
172. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2354-63.
173. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/ umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 1995; 92: 10119-22.
174. Rubinstein P, Taylor PE, Scaradavou A et al. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells 1994; 20: 587-96.
175. Harris DT. Experience in autologous and allogeneic cord blood banking. J Hematother 1996; 5: 123-8.
176. Lazzari L, Corsini C, Curioni C et al. The Milan Cord Blood Bank and the Italian Cord Blood Network. J Hematother 1996; 5: 117-22.
177. Gluckman E, Thierry D, Traineau R. Blood banking for hematopoietic stem cell transplantation. J Hematother 1993; 2: 269-70.
178. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilicalcord- blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214-19.
179. Gluckman E, Rocha V, Boyer-Chammard A et al., for the Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997; 337: 373-81.
180. Wagner JE, Barker JN, DeFor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-18.
181. Rocha V, Cornish J, Sievers EL et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-71.
182. Gluckman E, Rocha V. Cord blood transplantation for children with acute leukemia: a Eurocord registry analysis. Blood Cells Mol Dis 2004; 33: 271-3.
183. Barker JN, Davies SM, DeFor T, Ramsay NKC, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957-61.
184. Jacobsohn DA, Hewlett B, Ranalli M et al. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant 2004; 34: 901-7.
185. Eapen M, Rubinstein P, Zhang MJ et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 2007; 369: 1947-54.
186. Sallan SE, Niemeyer CM, Billett AL et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 1989; 7: 1594-601.
187. Colleseli P, Rossetti F, Messina C et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice for isolated extramedullary. Bone Marrow Transplant 1994; 14: 821-5.
188. Messina C, Rondelli R, Valecchi MG et al. Autologous bone marrow transplantation for extramedullary relapse in childhood leukemia. The AIEOP Group and the FONOP. Italian Association of Pediatric Hemato/Oncology. Bone Marrow Transplant 1996; 2: 40-2.
189. Balduzzi A, Gaipa G, Bonanomi S et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. Leukemia 2001; 15: 50-6.
190. Uckun FM, Kersey JH, Haake R, Weisdorf D, Nisbit ME, Ramsay NK. Pre-transplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl Med 1993; 28: 1296-301.
191. Pui C-H, Gaynon PS, Boyett JM et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-15.
192. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM, for the Medical Research Council Working Party on Childhood Leukaemia. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-199. Br J Haematol 2002; 117: 306-14.
193. Sanders JE, IM HJ, Hoffmeister PA et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105: 3749-56.
194. Kosaka Y, Koh K, Kinukawa N et al. Infant acute lymphoblastic leukemia with MML gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527-34.
195. Pieters R, Schrappe M, De Lorenzo P et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant- 99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-50.
196. Robison LL, Nesbit ME, Sather HN et al. Down syndrome and acute leukemia in children: a ten year retrospective survey from Children's Cancer Study Group. J Pediatr 1984; 105: 235-42.
197. Ragab AH, Abdel-Mageed A, Shuster JJ et al. Clinical characteristics and treatment outcome of children with acute lymphoblastic leukemia and Down's syndrome: a Pediatric Oncology Group study. Cancer 1991; 67: 1057-63.
198. Blatt J, Albo V, Prin W et al. Excessive chemotherapy- related toxicity in children with Down syndrome and acute lymphoblastic leukemia [Letter]. Lancet 1986; 2: 914. 826 Chapter 56.
199. Peeters MA, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987; 146: 416-22.
200. Rubin CM, O'Leary M, Koch PA et al. Bone marrow transplantation for children with acute leukemia and Down syndrome. Pediatrics 1986; 78: 688-91.
201. Bassal M, La MK, Whitelock JA et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005; 44: 21-8.
202. Whitlock JA, Sather HN, Gaynon P et al. Clinical characteristics and outcomes of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005; 106: 4043-9.
203. Rubin CM, Mick R, Johnson FL. Bone marrow transplantation for the treatment of hematological disorders in Down's syndrome: toxicity and outcome. Bone Marrow Transplant 1996; 18: 533-40.
204. Arensen EB, Forde MD. Bone marrow transplantation for acute leukemia and Down syndrome: report of a successful case and results of a national survey. J Pediatr 1989; 114: 69-72.
205. Pawlowska AB, Davies SM, Orchard PJ, Wagner JE, Ramsay NKC. Unrelated donor transplantation for children with Down syndrome. Bone Marrow Transplant 1996; 18: 435-55.
206. Conter V, D'Angelo P, Rizzari C et al. High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome. Bone Marrow Transplant 1996; 17: 287-9.
207. Barquinero J, Witherspoon R, Sanders J et al. Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. Br J Haematol 1995; 90: 595-601.
208. Patton DF, Wilkowski C, Hanson CA. Epstein- Barr-virus-related post-bone-marrow-transplant lymphoproliferative disease: association with cytomegalovirus infection and Down syndrome donor marrow. Am J Pediatr Hematol Oncol 1989; 11: 429-32.
209. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-75.
210. Wagner JE, Vogelsang GB, Zehnbauer BA, Griffin CA, Shah N, Santos GW. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: 205-9.
211. Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304-13.
212. Chiang K-Y, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39-42.
213. Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710-17.
214. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84: 3603-12.
215. Borowitz MJ, Pullen DJ, Shuster JJ et al. Minimal residual disease detection in childhood precursor- B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 2003; 17: 1566-72.
216. Ross ME, Zhou X, Song G et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951-9.
217. Haferlach T, Kohlmann A, Schnittger S et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 106: 1189-98.
218. Hollerman A, Cheok MH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351: 601-3.
219. Flotho C, Coustan-Smith E, Pei D et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007; 110: 1271-7.
220. Uzunel M, Jaksch M, Mattsson J et al. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukemia. Br J Haematol 2003; 122: 788-94.
221. Schilham MW, Balduzzi A, Bader P. PD-WP of the EBMT. Bone Marrow Transplant 2005; 1: 49-52.
222. Sramkova L, Muzikova K, Fronkova E et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93-100.
223. Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-85.
224. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLAmatched sibling bone marrow transplants. Blood 1999; 94: 3941-6.
225. Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908-18.
226. Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237-47.
227. Grigg AP. Approaches to the treatment of Philadelphia- positive acute lymphoblastic leukemia. Bone Marrow Transplant 1993; 12: 431-3.
228. Stockschlader M, Hegewisch-Becker S, Kruger W et al. Bone marrow transplantation for Philadelphia- chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 663-7.
229. Chao NJ, Blume KG, Forman SJ, Snyder DS. Long term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: 3353-6.
230. Emminger W, Emminger-Schmidmeier W, Haas OA et al. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation. Bone Marrow Transplant 1992; 9: 313-18.
231. Blume KG, Forman SJ, Snyder DS et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation 1987; 43: 389-92.
232. Amylon MD, Co JP, Snyder DS, Donaldson SS, Blume KG, Forman SJ. Allogeneic bone marrow transplantation in pediatric patients with high risk hematopoietic malignancies early in the course of their disease. J Pediatr Hematol Oncol 1997; 19: 54-61.
233. Hilden JM, Frestedt JL, Moore RO et al. Molecular analysis of infant acute leukemia: MLL gene rearrangement and reverse transcriptasepolymerase chain reaction for t(4;11)(q21;q23). Blood 1995; 86: 3876-82.
234. Eapen M, Zhang MJ, Devidas M et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008; 22: 281-6.